Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation

CONCLUSION: Incremental costs of progression to mCRPC are significant, with the majority of costs driven by higher PC-related costs. Using contemporary data, this study highlights the importance of utilizing effective therapies that slow progression and reduce healthcare resource demands despite the initial investment in treatment costs.PMID:38204397 | DOI:10.1080/13696998.2024.2303890

Source: Journal of Medical Economics - January 11, 2024 Category: Health Management Authors: Deborah R Kaye Ibrahim Khilfeh Erik Muser Laura Morrison Frederic Kinkead Ana Urosevic Patrick Lefebvre Dominic Pilon Daniel J George Source Type: research